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1. Introduction
   Africa South of Sahara is still the World’s most 
highly affected region with HIV/AIDS and accounts for 
approximately 70% of the global disease burden[1]. It is now 
about ten years since the commencement of antiretroviral 
therapy (ART) scales up in most parts of this continent but 
only 40% of those who need the service are reached[2]. Care 
and treatment to people living with HIV/AIDS (PLHIV) has 
improved the outcome of the disease in both developed and 
developing countries by reducing significantly the mortality 
rates[3-8].
   Rapid scale up of ART services in Tanzania together 
with other parts of Africa face challenges which affect the 
delivery of the expected services to people in need. These 
includes shortages of skilled and experienced personnel; 
lack of sustainable funding; low coverage in rural 
settings; low socioeconomic status among PLHIV; effects 
of stigma; ART adherence issues; ART drug resistance and 
immunological failure (IF) among people on highly active 
antiretroviral therapy (HAART)[9-12].
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Objective: To determine socio-cultural, demographic and highly active antiretroviral therapy 
(HAART) program-related factors associated with immunological failure (IF) among clients on 
HAART in Dar es Salaam care and treatment clinics.
Methods: A 1:2 matched case control study was done from February to April 2012 in HIV/AIDS 
care and treatment clinics in Dar es Salaam. Data were collected from National AIDS Control 
Program (NACP) data base and patient’s charts to obtain 60 sets of study participants who were 
interviewed using the structured questionnaire. Data analysis was done by using EPI Info 3.5.1 
version.
Results: The mean age of all study participants was (42.00依9.07) years with 35% (63) being males. 
History of poor antiretroviral therapy (ART) adherence due to exposure to drug holiday with loss to 
follow up (OR=11.96; 95% CI=2.07-69.26), history of changing care and treatment clinics (OR=12.07; 
95% CI=2.10-69.27) and the lack of treatment supporter (OR=23.26; 95% CI=1.85-291.66) were found 
to be strongly associated with the occurrence of first line HAART-IF.
Conclusions: HAART-IF in Dar es Salaam is associated with ART programmatic and patients’ 
centered challenges. There is a need to review the approaches on ensuring ART adherence, 
clients follow up and referral system so as to reduce the incidence of IF as we move to a more 
decentralized peripheral drug picks clinical initiative.
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   Treatment IF is a state where the clients who have been on 
ART experience 50% drop of the CD4 count or return to the 
baseline count in six month with a history of good adherence 
to treatment[13].
   Studies in East Africa show a high prevalence of IF ranging 
from 8% to 57% among clients on first line HAART  and 
furthermore the magnitude increases as the time of follow 
up increases[14-16]. It is well known that virological failure 
is a better marker of HAART failure as opposed to IF[14], but 
financial constraints hinder universal access to this method 
in many resource limited settings like Tanzania making IF a 
pivotal marker not only to predict virological failure but also 
to guide change of the treatment regimen.
   Non adherence to treatment has been reported to be 
major cause of IF[14,16], whereas stigma, food security, social 
support, income and tuberculosis co-morbidity have been 
reported to affect ART adherence[15,17-20]. Despite evidence 
from other areas on the socio-cultural and demographic 
factors as well as HAART program-related challenges which 
partly or wholly result into treatment IF, little is known 
among HIV/AIDS clients attending care and treatment clinics 
(CTC) in Dar es Salaam, Tanzania.
2. Materials and methods
2.1. Study design and sampling process
   A 1:2 matched case control study was conducted at 
Mwananyamala, Temeke, Mnazi Mmoja and Mbagala 
Hospitals in Dar es Salaam from February to April 2012 in 
HIV/AIDS CTC. Data collection process used the National AIDS 
Control Program (NACP) data base together with patient’s 
charts to sort 180 study participants [60 qualified cases 
of IF and 120 controls (without IF)]. The study cases were 
the clients on first line HAART for at least one year with 
immunological failure (50% drop of the CD4 count from 
the peak value in six month or return to the baseline CD4 
count). The study controls were clients on the first line 
HAART for at least one year of follow up with good treatment 
immunological response (i.e. clients without any history CD4 
count drop of more than 25% in a period of six month). The 
obtained cases were matched with two controls by using sex, 
age group, baseline CD4 count and ART follow up time as 
matching variables.
2.2. Data collection techniques and tools
   The data was collected by using a structured questionnaire 
administered equally to both cases and control. Data 
pertaining to social demographic variables, ART baseline 
information, adherence, stigma assessment, history of 
ART loss to follow up, HIV co-morbidity, self-reported 
food security, nutrition, income and social support were 
inquired. The measurement of HIV related stigma was 
made by using three important parts of Berger’s scale of 
HIV stigma[21]. The scores were given using Likert’s scale 
(strongly agree; agree; disagree; strongly disagree) with a 
score range of 16-64 points as a minimum to the maximum. 
The study members with scores less 32 were considered less 
stigmatized and individuals with the scores more than or 
equal to 32 were considered as more stigmatized. History of 
adherence to antiretroviral drugs for the past six month was 
sought basing on patient clinical files and self-reporting. 
Any history of adherence of less than 95% was considered 
poor. Assessment of food security was based on physical and 
financial accessibility foods throughout the year and three-
day nutritional history was taken. The income of less than 
one USD per person per day in the family was considered as 
exposure to low income. 
2.3. Data analysis
   Data pertaining to socio-demographic characteristics, 
ART baseline information, adherence status, stigma, food 
security and other variables were entered into Excel sheet®, 
cleaned and exported to Epi info software version 3.5.1 for 
analysis according to the objectives of the study. Frequency 
distribution of the socio-demographic characteristics were 
described and compared the cases with the controls. The 
bivariate analysis using maximum likelihood estimates of 
the categorical variables was done using a cross tabulation 
of the cases and the controls to determine the association of 
the variables. Odds ratio was calculated with their respective 
confidence interval. Furthermore, the variables with P<0.05 
in the bivariate analysis were subjected to conditional 
logistic regression to get the independent predictors of IF 
measured by adjusted odds ratio (aOR) together with their 
respective confidence interval.
2.4. Study clearance and ethical considerations
   The study ethical clearance was obtained from the 
Institutional Review Board (IRB) of the Muhimbili University 
of Health and Allied Sciences. A written informed consent 
from each ART client was sought and confidential handling 
of clinical information was carefully observed by using 
anonymous codes.
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3. Results
   Of all study participants 63 (35%) were males whereas 
21 (33.33%) of all study cases with IF were males. More 
than two third of the study population aged between 31 
and 50 with the overall mean age of (42.00依9.07) years. 
Furthermore, 79 (43%) were married with more than one 
third being petty traders with primary school education 
(Table 1).
   Bivariate analysis found an association between IF 
and prior history of CTC change (aOR=7.09, 95% CI=3.18-
17.59), HIV stigma (aOR=2.52, 95% CI=1.27-5.23), limited 
HIV status disclosure (aOR=3.11, 95% CI=1.19-9.53) and 
lack of disclosure of the HIV status to the family members 
(aOR=3.49, 95% CI=1.59-8.34). Moreover, IF was also 
associated with negative public attitude about people 
living with HIV (aOR=3.35, 95% CI=1.59-7.60), history of 
poor ART adherence in six month (aOR=13.11, 95% CI=4.29-
55.24) and ART poor adherence in past one year (aOR=13.74, 
95% CI=5.21-45.79). Furthermore, bivariate analysis also 
found a strong association between IF and exposures to 
ART drug holidays with loss to follow up (aOR=9.55, 95% 
CI=3.87-27.49) and lack of treatment supporter (aOR=26.79, 
95% CI=7.49-167.12) (Table 2). 
   Upon conditional logistic regression analysis, exposure 
to drug holiday which is associated with ART loss to follow 
up (OR=11.963 1; 95% CI 2.06-69.25), history of changing 
CTC (OR=12.072 2; 95% CI 2.10-69.27) and lack of treatment 
supporter(OR=23.256 6; 95% CI 1.85-291.68) were found to 
be independent predictors of the occurence of first line 
HAART-IF (Table 3).
Table 1
Social demographic characteristics of the study participants.








Age  (years) ≤30  9 (40.91) 13 (59.09)  22 (100)
0.829 6 0.842*
31-40 19 (31.15) 42 (68.85)  61 (100)
41-50 20 (31.75) 43 (68.25)  63 (100)
≥51 12 (35.29) 22 (64.71)  34 (100)
Sex Male 21 (33.33) 42 (67.67)   63 (100)
0.000 0 1.000*Female 39 (33.33) 78 (67.67) 117 (100)
Marital 
status
Married 24 (30.38) 55 (69.62)  79 (100)
Never married  7 (26.92) 19 (73.08)  26 (100)
2.600 0 0.630
Widowed  9 (32.14) 19 (67.86)  28 (100)
Cohabiting  3 (42.86)  4 (57.14)   7 (100)
Divorced 17 (42.50) 23 (57.50) 40 (100)
Education No formal education 1 (8.30) 11 (91.70) 12 (100)
9.370 0 0.520
Primary 42 (33.10) 85 (66.90) 127 (100)
Secondary 10 (33.30) 20 (66.67)  30 (100)
College  5 (55.60)  4 (44.40)   9 (100)
University     2 (100)    0 (0.00)   2 (100)
Occupation Peasant  5 (38.46)  8 (61.54) 13 (100)
1.900 0 0.860
Petty trader 17 (29.31) 41 (70.69) 58 (100)
Business 12 (34.29) 23 (65.71) 35 (100)
Employment 16 (35.56) 29 (64.44) 45 (100)
House wife   6 (28.57) 15 (71.43) 21 (100)
Unemployed   4 (50.00)  4 (50.00) 08 (100)
*: Matched variables; **: Fisher’s exact was used where appropriate.
Table 2








Alcohol use  1.00 0.43-2.27   0.495
History of CTC change  7.09  3.18-17.59 <0.001
Berger`s HIV stigma  2.52 1.27-5.23   0.004
Unprotected sex  3.35 1.24-9.83   0.008
PITC mode of CTC entry  1.22 0.65-2.32   0.267
Unsatisfactory diet  1.00 0.45-2.14   0.495
Limited disclosure  3.11 1.19-9.53   0.009
Insufficient income to carter for food  1.78 0.78-4.06   0.085
Living with a sexual partner  1.48 0.41-5.17   0.266
Negative self-image  3.78   0.94-18.46   0.029
Post exposure prophylaxis  2.16 0.62-7.79   0.112
Public attitude about people living with HIV  3.35 1.59-7.60 <0.001
Adherence below 95% in six month 13.11   4.29-55.24 <0.001
Lack of treatment supporter 26.79     7.49-167.12 <0.001
ART straight forward  1.34  0.46-4.42   0.309
HIV status disclosure after six month  2.32  0.96-6.08    0.036
ART  poor adherence  in past one year 13.74    5.21-45.79 <0.001
History of TB infection  2.00    0.21-19.21   0.259
Drug holiday with loss to follow up  9.55    3.87-27.49 <0.001
Lack of family disclosure  3.49   1.59-8.34 <0.001
No disclosure to the sexual partner  1.09   0.54-2.18   0.406
Personal income of less than one USD per day  0.84   0.29-2.34   0.390
   
Table 3
Conditional logistic regression of IF predictor variables 
Exposure variable OR  95% CI P-value
History of change of CTC point  12.072 2  2.10-69.27 0.005
Berger’s HIV stigma   0.064 8 0.00-2.82 0.155
Unprotected sex   1.287 0  0.08-20.41 0.858
Limited disclosure   1.839 3  0.15-23.18 0.637
Drug holiday  11.963 1   2.06-69.25 0.006
Limited family disclosure   1.126 5 0.27-4.64 0.869
Negative self image   0.932 0   0.02-36.12 0.969
Negative public attitude  28.157 1      0.62-1286.59 0.087
Six month poor adherence   3.220 9     0.06-161.39 0.558
HIV status disclosure after six month   1.897 8   0.19-18.61 0.582
Lack of treatment supporter 23.256 6    1.85-291.68 0.015
ART  poor adherence  in past one year   4.666 3   0.27-81.27 0.290
4. Discussion
   This study compared various demographic variables 
among patients attending CTC on the immunological 
outcome and found not any significant difference between 
the case and control groups. Poor adherence to ART was 
strongly associated with IF in the present study, whereas 
both IF and virological failure were also associated with 
poor adherence in other studies[16,19,22]. HIV related 
stigma remains one of the challenges facing Sub Saharan 
ART programs. This study revealed an association in 
the overall Berger’s HIV stigma, disclosure concerning 
factors and perception on public attitude about PLHIV 
and subsequent IF among the first line HAART clients 
at the bivariate analysis. Studies in Sub Saharan Africa 
have shown how HIV stigma has contributed to not only 
to poor ART adherence but also affecting the ART health 
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seeking behavior among PLHIV[23-25]. The present study 
showed that the changes in CTC clinics and exposure to 
drug holidays are strongly associated with IF. Problems 
related to ART loss to follow up clients and its effect in the 
performance of ART program was also shown in another 
study in Malawi[26]. The aforementioned constrains 
emphasize the need to strengthen the CTC tracking system 
and thus maximize retention rates among the clients on 
HAART. Furthermore, we speculate that loss to follow 
up may partly be attributing to the escalating burden of 
HIV1 drug resistance as shown in the two recent sub-
Saharan Africa studies with Uganda (12.3%) and Tanzania 
(14.8%) showing the highest prevalence among treatment 
naive patients[27,28]. In the light of these findings, one of 
factors which may cause high rate HAART resistance in 
Tanzania as shown in the Mwanza study[28], could be the 
fact that some of the study participants were possibly 
not truly HAART naive but rather they had been exposed 
to antiretroviral drugs and due to frequent changes in 
CTC, they may undisclosed the information and thus re-
registered as new clients.
   The conditional logistic regression analysis of socio-
economic variables showed that lack of ART treatment 
supporter among the first line HAART clients was strongly 
associated with IF. This finding is in consistent with 
another similar study which finds an association between 
social support and prescribed drug adherence[29]. 
Furthermore, positive social supports, including being 
married and family support have clearly been associated 
with adherence to ART as many studies from different 
parts of the world[18,30-33]. 
   Though not shown in the present study, many studies 
in sub-Saharan Africa have shown that food insecurity 
contributes to poor ART adherence and subsequent 
undue treatment outcome among these HIV patients on 
HAART[20,34,35]. Other studies in sub-Saharan Africa have 
reported high inconsistence in condom use and tendency 
to underreport issues pertaining to sexuality among client 
on HIV care and treatment, situations which may mislead 
a truly behavioral picture regarding IF as shown in the 
present study[36-39].
   Lack of viral load measurements in this study due to 
financial constraints could have been of interest so as to 
further delineate its contribution to IF. 
   Immunological failure among patients on HAART 
attending CTC in Dar es Salaam is due to both ART 
programmatic and patients’ centered challenges with poor 
adherence to HAART due to exposure to drug holiday with 
loss to follow up, history of changing of CTC and the lack 
of treatment supporter being independent predictors of 
IF. There is a need to review the approaches on ensuring 
ART adherence, clients follow up and referral system so 
as to reduce the incidence of immunological failure as we 
move to a more decentralized peripheral drug pick clinical 
initiative.
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